PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-272.88%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-59.22%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-272.88%
Negative net income growth while AXSM stands at 88.11%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-252.38%
Negative EPS growth while AXSM is at 92.63%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-313.33%
Negative diluted EPS growth while AXSM is at 92.63%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
10.47%
Share reduction more than 1.5x AXSM's 62.59%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
-20.54%
Reduced diluted shares while AXSM is at 62.59%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
-64.88%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-57.97%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-16444.97%
Negative 10Y OCF/share CAGR while AXSM stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-31629.64%
Negative 5Y OCF/share CAGR while AXSM is at 0.00%. Joel Greenblatt would question the firm’s operational model or cost structure.
-47124.26%
Negative 3Y OCF/share CAGR while AXSM stands at 0.00%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-24144.03%
Negative 10Y net income/share CAGR while AXSM is at 0.00%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-61703.68%
Negative 5Y net income/share CAGR while AXSM is 0.00%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-67595.61%
Negative 3Y CAGR while AXSM is 0.00%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
No Data
No Data available this quarter, please select a different quarter.
1169.73%
Equity/share CAGR of 1169.73% while AXSM is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
1236.68%
Equity/share CAGR of 1236.68% while AXSM is zero. Bruce Berkowitz sees if minor gains can snowball into a bigger lead soon.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-18.44%
Negative asset growth while AXSM invests at 0.00%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-50.41%
We have a declining book value while AXSM shows 0.00%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-100.00%
We’re deleveraging while AXSM stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
88.49%
R&D growth drastically higher vs. AXSM's 59.68%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
34.89%
SG&A declining or stable vs. AXSM's 99.21%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.